Not a member yet? Register here
Ivosidenib plus azacitidine for patients with IDH1-mutated acute myeloid leukaemia
Zanubrutinib as a new treatment option for patients with Waldenström macroglobulinaemia
FDA approval for brentuximab vedotin for children with high-risk Hodgkin lymphoma
Amsterdam scientists investigate why immunotherapy fails in Chronic Lymphocytic Leukaemia
INREBIC® (FEDRATINIB) NOW REIMBURSED FOR PATIENTS WITH MYELOFIBROSIS
Rondaptivon pegol can be used as a treatment for severe and nonsevere haemophilia A
Index latest issue
Highlights in chronic lymphocytic leukaemia
Highlights in chronic myeloid leukaemia
Highlights in lymphoma
Long-term outcomes of isatuximab in high-risk multiple myeloma
Highlights in multiple myeloma
Navigating secondary acute myeloid leukaemia in 2023
Highlights in acute myeloid leukaemia and myelodysplastic syndromes
Highlights in acute lymphoblastic leukaemia
New haematology reimbursements in Belgium
High-frequency vincristine-steroid pulses do not benefit outcomes in acute lymphoblastic leuka...
Wearable device for tracking temperature of paediatric blood cancer patients at home
Axi-cel as an effective second-line treatment for R/R LBCL patients ineligible for transplanta...
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic ...
Cancer-associated thrombosis awareness survey (ECPC)
Canakinumab in children and young adults with sickle cell anaemia
Long-term remission rates after treatment with tisagenlecleucel in paediatric and young adult ...
Encouraging results with loncastuximab tesirine plus rituximab for DLBCL patients
New Danish app helps doctors in making better decisions for leukaemia patients